Background: Pulmonary arterial hypertension (PAH) is a progressive vascular disorder with a high mortality. Clinical experience and small case series suggest thrombocytopenia may be frequent in this population and associated with a poor prognosis. We sought to estimate the prevalence of thrombocytopenia in patients with PAH and characterize its association with disease characteristics and patient outcome. Methods: Single center cohort study of 714 incident adult patients with Group 1 PH who were evaluated for baseline platelet count at the time of diagnosis. Pts were stratified into three groups: normal platelet count (>150 £ 10 9 /L), Grade 1 thrombocytopenia (75À149 £ 10 9 /L) and Grade 2À4 thrombocytopenia (<75 £ 10 9 /L). Results: The median platelet count was 209 £ 10 9 /L (IQR 163, 264). There were 572 (80%) pts without thrombocytopenia, 107 (15%) with Grade 1 and 35 (5%) with Grade 2À4 thrombocytopenia. The median pt age was 55 years (IQR 44À65) with no difference between platelet groups (p = 0.85). Men were more likely to have thrombocytopenia (62, 34%) than women (80, 15%, p < 0.0001). Thrombocytopenia was frequent with portopulmonary PAH (84%) as opposed to idiopathic PAH (iPAH; 14%) or connective tissue disease associated PAH (12%). Platelet counts were not associated with functional class symptoms, the degree of right ventricular enlargement or dysfunction or tricuspid regurgitation by echocardiography. Invasive hemodynamics of right atrial pressure, mean pulmonary artery pressure and pulmonary vascular resistance were also similar between platelet groups. Thrombocytopenia was associated with higher mortality in iPAH patients (age-and sex-adjusted 5 year mortality [HR 1.95 (1.20, 3 .08) p = 0.008] but not in other etiology groups. In a multivariate model of iPAH patients (adjusted for age, sex, DLCO, PVR, creatinine and 6MW distance) thrombocytopenia was most predictive of 5-year mortality [HR 1.68 (1.32, 2.12), p < 0.0001]. Conclusion: Thrombocytopenia in the context of iPAH portends a poor prognosis and is a simple independent factor to consider in judging severity of disease.
Introduction
Pulmonary arterial hypertension (PAH) is a disease characterized by pulmonary vascular remodeling with clinical progression typically correlating with right heart failure. Thrombocytopenia in pulmonary hypertension has been described in the literature on few occasions in small retrospective case series. In the largest cohort study available Chin et al describe an independent association of thrombocytopenia with epoprostenol use that appears to be dose dependent in a study of 87 PAH patients. 1 Additionally, they note an independent association of thrombocytopenia with more severe hemodynamics. The latter finding may be a result of progressive right heart failure leading to portal hypertension, splenomegaly and platelet sequestration. Several cases of PAH associated with microangiopathic hemolytic anemia and thrombocytopenia have also been described in the literature. 2, 3 More recently, Mojadidi and colleagues have demonstrated an association of thrombocytopenia with poor prognosis in an echocardiographically defined cohort of severe pulmonary hypertension. 4 A smaller study of 65 idiopathic PAH patients suggested platelet count below the mean (200 £ 10 9 /L) was a significant prognostic variable. 5 Probably due to sample size limitations this study failed to confirm other traditional prognostic variables. As therapeutic options for PAH continue to progress, risk stratification of patients utilizing prognostic variables is imperative. The minimally invasive nature of laboratory testing with platelet counts is ideal given the universal availability of Abbreviations: BNP, brain natriuretic peptide; eGFR, estimated glomerular filtration rate; PAH, pulmonary arterial hypertension; PFT, pulmonary function test(ing); RHC, right heart catheterization; WHO, World Health Organizationthe test. In the present study we sought to estimate the prevalence of thrombocytopenia, characterize the clinical and hemodynamic factors of patients with this co-morbid diagnosis, and determine its association with outcome in patients diagnosed with PAH.
Methods

Study sample
This study was conducted with use of our institutional PAH registry. We identified all adult patients (18 years) diagnosed with PAH at our tertiary care referral-based academic practice between 1/1/ 1995 and 12/31/2009. Diagnosis of PAH was based on current practice criteria 6 and diagnosis date was set at the time of first clinic visit in which diagnosis at our center was confirmed. Patients were not on PH therapy. Data entry occurred after the complete initial patient evaluation. Data presented here were collected at, or near, diagnosis. The etiology of PAH was recorded for each patient: idiopathic or familial PAH (iPAH), PAH associated with connective tissue disease (cPAH), portopulmonary PAH (poPAH), PAH associated with congenital heart disease or other PAH. Platelet count was assessed in all patients at the time of PAH diagnosis. Patients in whom a platelet count was not available within 6 months of diagnosis were excluded (n = 34). Classification of thrombocytopenia was based upon the Common Terminology Criteria for Adverse Events of the National Cancer Institute. 7 No thrombocytopenia was considered when platelet counts were 150 £ 10 The primary endpoint of this study was 5-year mortality. Survival data was obtained from combined review of the medical record and cross referencing with the social security national death index. Patient data was censored at 5 years or at the time of heart/ heartlung or liver organ transplantation. Mortality status at 5 years was available from the medical record in greater than 95% of the cohort. All patients agreed to the use of their medical information for research purposes and the study was approved by the Mayo Foundation Institutional Review Board.
Statistical analysis
Continuous variables are presented as mean § standard deviation and categorical variables as the absolute number and percentages. Variables were compared utilizing unpaired t-test, chi-squared tests or ANOVA. Linear regression analysis was used for correlation assessment of continuous variables. Cox-proportional hazard models were used to assess predictors of 5-year mortality. Results are presented as hazard ratios (HRs) with 95% CIs. Models were developed using stepwise techniques with consideration of clinically relevant variables having p < 0.1 by univariate analysis. Variables were retained in the model at a threshold of p < 0.1. For persons with incomplete data, additional categorical variables (test performed, test not performed) were included. Long-term follow-up of patients is presented based on the Kaplan-Meier product-limit method and compared between groups using the log-rank test. p values <0.05 were considered statistically significant. All data analyses were performed using JMP, version 10.0 (SAS Institute Inc., Cary, North Carolina).
Results
Clinical characteristics
There were 714 patients who met criteria for inclusion. Platelet count was obtained a mean of 8.6 days (SD 23.4 days) from PAH diagnosis. Thirty-four patients were excluded as no platelet count was available within 6 months of PAH diagnosis. The median platelet count was 209 £ 10 9 /L (IQR 163, 264). The majority of patients had no thrombocytopenia (572, 80.1%). Grade 1À4 thrombocytopenia was present in 107 (15.0%), 28 (3.9%), 5 (0.7%) and 2 (0.3%) patients, respectively. Given the small number of patients with Groups 2À4 thrombocytopenia, these groups were combined for analyses. The presence and severity of thrombocytopenia varied across etiology groups as shown in Fig. 1 . All patients were within 3 months of diagnosis. The majority (96%) were newly diagnosed and not on any pulmonary hypertension therapy. Twenty-nine patients had been diagnosed recently and referred to the Mayo PH clinic and had been commenced on some therapy when seen (8/29 on prostaglandin analogs, 11 on endothelin receptor antagonists and 17 on PDE 5 inhibitors). The use of therapy was not associated with platelet counts.
The median patient age was 55 years (IQR 44À65) with no difference between platelet groups (p = 0.85). The distribution of demographic, clinical, echocardiographic and hemodynamic variables by presence and grade of thrombocytopenia are presented in Table 1 . The presence of thrombocytopenia was more common in men (62, 34%) than women (80, 15%, p < 0.0001). The differences in thrombocytopenia rates by sex were larger related to higher rates of thrombocytopenia in patients with idiopathic PAH (Table 2) .
Six-minute walk testing was more frequently completed in patients without thrombocytopenia (78% vs. 65%, p = 0.009); in those who completed a walk, there was no difference in the mean distance walked. Moderate or greater right atrial enlargement was more common in patients without thrombocytopenia (67% vs 57%, p = 0.046). There was no difference in other right heart parameters by echocardiography. Cardiac index was lower in patients without thrombocytopenia (2.5 L/min/m 2 vs 2.7, p = 0.02) but no difference was seen in other factors assessed at right heart catheterization. There was no relationship between platelet count and right atrial pressure at cardiac catheterization (r 2 = 0.004; p = 0.11).
Factors associated with all-cause mortality
One, three and five-year survival were 81.9, 62.9 and 50.5% respectively for the study cohort. The presence of thrombocytopenia was associated with increased mortality (HR 1.56; 95% CI 1.20À2.00). When stratified by etiology, the presence of thrombocytopenia was associated with mortality only in iPAH patients (unadjusted HR 2.34; 95% CI 1.53À3.45). Kaplan-Meier survival curves for the iPAH patient cohort are shown in Fig. 2 . Several predictors of increased mortality were observed in univariate risk assessment of the iPAH cohort (Table 3) . Fig. 1 . Distribution of thrombocytopenia presence and severity by PAH etiology; p < 0.0001 for between group differences.
Only a minority of patients in the cohort had simultaneous measures of brain natriuretic peptide (BNP) and platelet count (n = 259, 36%). In those in whom no BNP was available (n = 453), the univariate risk ratio per thrombocytopenia grade was 1.46 (1.16À1.80); p = 0.001 and in those that BNP was available (n = 259) the risk ratio per thrombocytopenia grade was 1.23 (0.83À1.72); p = 0.28. In a model that incorporated BNP elevation (presence or absence) and thrombocytopenia grade in these 256 patients with simultaneous measures, there appeared to be independent risk association with a risk ratio per thrombocytopenia grade of 1.34 (0.90À1.91); p = 0.14 and a risk ratio for elevation in BNP 2.38 (1.49À3.99); p = 0.0002.
When all variables of interest were incorporated into a multivariate model, the following variables remained predictive of outcome: 6MWD, pulmonary vascular resistance, DLCO, creatinine and progressive thrombocytopenia (Fig. 3) . Increasing grade of thrombocytopenia (from none to grade 1 to grade 2À4) was the most predictive (HR 1.68; 95% CI 1.32À2.12).
Discussion
Thrombocytopenia occurs in up to 20% of patients with PAH. Not unexpectedly, thrombocytopenia is common in poPAH (>80%) and relatively uncommon in other PAH etiology groups (<20%). The frequency of thrombocytopenia in poPAH is slightly greater than the 64% reported in cirrhotic patients. 8 Thrombocytopenia grade was not predictive of survival in our poPAH cohort. Men tended to have higher rates of thrombocytopenia in iPAH, but the reasons of this are unclear.
Multiple factors may lead to thrombocytopenia in PAH patients. Progressive right heart failure resulting in congestive hepatopathy and associated splenomegaly with platelet sequestration is one prominent theory. We found no relationship between right atrial pressure and platelet count in the present study. Neither were typical indicators of progressive right heart failure associated with thrombocytopenia in our analysis. These findings raise the hypothesis that unlike most novel biomarkers in PAH, platelet count is not a marker of right ventricular systolic function. Measures such as (NT-pro) brain natriuretic peptide, and even variables such as sodium and creatinine all likely reflect RV systolic function, which make them useful measures in establishing prognosis in pulmonary arterial hypertension. So if thrombocytopenia does not predict right ventricular systolic function, what are they a marker of and why do they associate with prognosis? Plausibly, the platelet count may actually be a variable that reflects the vascular pathobiology in the lung. It has been suggested, the thrombocytopenia may originate as result of defects in platelet production or as a result of peripheral platelet clearance. 9 Some reports have suggested thrombocytopenia may arise from sequestration and fragmentation, which may result with hemodynamic pulmonary vascular stress in the plexiform lesions characteristic of PAH. 2, 3 These lesions are atypical in PH associated with left heart disease or chronic hypoxia. Our study was restricted to PAH, but further study of thrombocytopenia in other PH etiologies compared to PAH patients would be of interest. Significant perturbations in a variety of stimulatory and inhibitory pulmonary vascular signals are recognized in patients with pulmonary arterial hypertension, many of which affect platelet activation, including enhanced thromboxane A2, and down regulated endothelial derived prostacyclin and nitric oxide. 9À12 Drug therapy has also been thought to contribute to thrombocytopenia in PAH patients. Our study assessed platelet count at the time of PAH diagnosis and hence treatment cannot explain the results seen.
In our patient cohort, survival was slightly less than that of other recently published cohorts.
13À15 This is likely explained by the different proportion of patients with cPAH and poPAH in our cohort compared to the other studies. The results from recent cohorts, ours included, show significant progress in pulmonary hypertension treatment with survival markedly improved compared to initial data from three decades ago. 16 Multiple prognostic factors are utilized by clinicians when individualizing patient treatment recommendations. 13, 17, 18 In a recent analysis Mojadidi and colleagues suggested an independent prognostic role of moderate-severe thrombocytopenia in an echocardiographically defined PH group. 4 Our study only assessed group 1 PH with similar findings restricted to iPAH patients. This same finding was not appreciated in patients with other etiologies of PAH. Our data are consistent with the results of Taguchi et al who reported a survival difference in patients with iPAH and a platelet count above versus below the mean (200 £ 10 9 /L). 5 Our study added to their data by providing a large cohort of patients.
We were able to demonstrate the independent negative impact of thrombocytopenia on survival in iPAH patients while confirming other traditional adverse prognostic variables. We also show no prognostic value of thrombocytopenia in other etiologies of PAH. This may reflect alternative mechanisms for the development of thrombocytopenia in patients with cPAH and poPAH rather than reflecting increased severity of PAH.
Limitations
Our study is a single-center retrospective analysis. The practice patterns specific to our center may influence the results. Additionally, the study is of patients evaluated at a PH Care Center and as a result may be prone to survival bias. These factors are unlikely to substantially affect the study conclusions given the similarities between our study and other published cohorts. Whether platelet counts vary over time including in response to chronic drug therapy and whether any changes in platelet counts are associated with disease progression and outcome could not be assessed in this study and warrants further investigation. Plausibly, serial changes in platelet counts over time may serve as a marker of changes in the patients' underlying pulmonary vascular pathobiology. Further studies should assess serial platelet counts in patients with PAH. All patients included were newly diagnosed. Whether platelet counts have similar relationship to disease characteristics or outcome in patients on therapy with chronic disease needs to be tested. These questions all warrant further investigation. Finally, we are unable to comment on potential implications of different platelet counting systems, as there was no standardization in the specific method of platelet count measurements across patients.
Conclusion
While survival in PAH has improved significantly in the modern era, PAH remains a disease characterized by high mortality in a relatively young population. Continued improvement in treatment with new therapies will be advanced by accurate assessment of patient risk. The development of novel prognostic markers in PAH should remain a priority. In patients with iPAH, we show that thrombocytopenia is independently associated with reduced 5-year survival. Our study demonstrates the prognostic role of platelet testing in patients with newly diagnosed iPAH. 
